Are you over 18 and want to see adult content?
More Annotations
![A complete backup of stopparodontoz.ru](https://www.archivebay.com/archive/117cbef5-85fd-48c0-bc5a-f2abe16c1b2d.png)
A complete backup of stopparodontoz.ru
Are you over 18 and want to see adult content?
![A complete backup of tablasdemultiplicar.com](https://www.archivebay.com/archive/09b055e0-2124-421b-8224-119076914ce6.png)
A complete backup of tablasdemultiplicar.com
Are you over 18 and want to see adult content?
Favourite Annotations
![فروشگاه اینترنتی آفسال – فروشگاه اینترنتی آفسال](https://www.archivebay.com/archive/c9ad907a-836d-421c-a6e9-de0eceb5a23d.png)
فروشگاه اینترنتی آفسال – فروشگاه اینترنتی آفسال
Are you over 18 and want to see adult content?
![MacGyver Deconstructed](https://www.archivebay.com/archive/ad806237-f8c1-4716-98b8-09acde53293d.png)
MacGyver Deconstructed
Are you over 18 and want to see adult content?
![Kape Internships – Guaranteed Internships in London, UK](https://www.archivebay.com/archive/f66e3846-8fc5-4c4c-a836-712f56fc7551.png)
Kape Internships – Guaranteed Internships in London, UK
Are you over 18 and want to see adult content?
![Manage, Migrate, & Protect Your SharePoint & Office 365 Data | AvePoint](https://www.archivebay.com/archive/81282582-83a1-4e46-b5a9-ea38e7dfafcf.png)
Manage, Migrate, & Protect Your SharePoint & Office 365 Data | AvePoint
Are you over 18 and want to see adult content?
![Web development tutorials | w3resource](https://www.archivebay.com/archive/36e5534d-ccb1-474c-837c-64ddf9f5b43b.png)
Web development tutorials | w3resource
Are you over 18 and want to see adult content?
Text
FEEL THE SCIENCE
Almirall in Numbers. Our devotion to science and people can be measured. +100. Countries where we help patients. +1,780. Employees (53% women) 13. Countries Present within Europe and US. €78,9 M.OUR PRODUCTS
Vitamin B2. Vitamin B6. Vitamin C. Vitamin E. Xanthinol furosemide. Therapeutic Area Alimentary tract and metabolism Antiinfectives for systemic use Cardiovascular system Dermatologicals Genito urinary system and sex hormones Immunostimulants Metabolism Musculo-skeletal system Nervous system Respiratory system Systemic hormonalpreparations.
ANNUAL REPORTS
Annual Report. Our yearly figures. Discover how we have performed in 2020 and where we are heading in 2021. Information issued by the company to the National Stock Exchange Commission (CNMV). Annual Report 2020 PDF (7MB) Annual Report 2019 PDF (6.7MB) Annual Report2018 PDF (2.5MB)
OUR NOBLE PURPOSE
Our noble purpose. Transform the patients' world by helping them realize their hopes and dreams for a healthy life. We are a leading skin health-focused biopharmaceutical company that partners with healthcare professionals to apply science to overcome patients’needs
BOARD OF DIRECTORS
Joan Figueras Carreras. Vice Secretary (non-member) Mr. Figueras holds a Bachelor’s Degree in Laws from the Universitat de Barcelona and joined Almirall in 1993 as Senior Director of Legal Department, working in that position until 2013. Since then he is General Counsel of the company and Vice-Secretary of the Board of Directors. ALMIRALL AND MC2 THERAPEUTICS ENTER A LICENSE BARCELONA, Spain and COPENHAGEN, Denmark. February 17th, 2021 – Almirall S.A. (BME: ALM), a global biopharmaceutical company and MC2 Therapeutics, a commercial stage pharmaceutical company developing a new standard within topical therapies for autoimmune and chronic inflammatory conditions, announced today an agreement under which MC2 Therapeutics has granted AlmirallMANAGEMENT BOARD
Mr. Pablo Álvarez has a PhD in Pharmacy, with a focus on Microbiology from the Complutense University of Madrid (Spain). He carried out a postdoctoral research at MIT (Massachusetts, United States) and he has also studied business and management at IESE Business School in Barcelona (Spain). Pablo joined Almirall in 2019 as Commercial ALMIRALL AND WUXI BIOLOGICS SIGN STRATEGIC COLLABORATION Barcelona, Spain January 9 th, 2020. Almirall, S.A. (ALM), and WuXi Biologics ("WuXi Bio") (2269.HK) have today announced the signing of an agreement. Through this collaboration Almirall embarks on its strategy to develop highly innovative biologic products for dermatology diseases including atopic dermatitis. IDENTITY MANAGER DASHBOARD Almirall Identity Access Copyright © 2021 Micro Focus. All rightsreserved.
ALMIRALL EXERCISES ITS OPTION WITH DERMIRA TO LICENSE BARCELONA, Spain and MENLO PARK, Calif. June, 25th 2019 . Almirall, S.A. (ALM) and Dermira, Inc. (NASDAQ: DERM) announced today that Almirall has exercised its option to license rights to develop and commercialize lebrikizumab for the treatment of atopic dermatitis and certain other indications in Europe. Almirall and Dermira previously entered into an option and license agreement inFEEL THE SCIENCE
Almirall in Numbers. Our devotion to science and people can be measured. +100. Countries where we help patients. +1,780. Employees (53% women) 13. Countries Present within Europe and US. €78,9 M.OUR PRODUCTS
Vitamin B2. Vitamin B6. Vitamin C. Vitamin E. Xanthinol furosemide. Therapeutic Area Alimentary tract and metabolism Antiinfectives for systemic use Cardiovascular system Dermatologicals Genito urinary system and sex hormones Immunostimulants Metabolism Musculo-skeletal system Nervous system Respiratory system Systemic hormonalpreparations.
ANNUAL REPORTS
Annual Report. Our yearly figures. Discover how we have performed in 2020 and where we are heading in 2021. Information issued by the company to the National Stock Exchange Commission (CNMV). Annual Report 2020 PDF (7MB) Annual Report 2019 PDF (6.7MB) Annual Report2018 PDF (2.5MB)
OUR NOBLE PURPOSE
Our noble purpose. Transform the patients' world by helping them realize their hopes and dreams for a healthy life. We are a leading skin health-focused biopharmaceutical company that partners with healthcare professionals to apply science to overcome patients’needs
BOARD OF DIRECTORS
Joan Figueras Carreras. Vice Secretary (non-member) Mr. Figueras holds a Bachelor’s Degree in Laws from the Universitat de Barcelona and joined Almirall in 1993 as Senior Director of Legal Department, working in that position until 2013. Since then he is General Counsel of the company and Vice-Secretary of the Board of Directors. ALMIRALL AND MC2 THERAPEUTICS ENTER A LICENSE BARCELONA, Spain and COPENHAGEN, Denmark. February 17th, 2021 – Almirall S.A. (BME: ALM), a global biopharmaceutical company and MC2 Therapeutics, a commercial stage pharmaceutical company developing a new standard within topical therapies for autoimmune and chronic inflammatory conditions, announced today an agreement under which MC2 Therapeutics has granted AlmirallMANAGEMENT BOARD
Mr. Pablo Álvarez has a PhD in Pharmacy, with a focus on Microbiology from the Complutense University of Madrid (Spain). He carried out a postdoctoral research at MIT (Massachusetts, United States) and he has also studied business and management at IESE Business School in Barcelona (Spain). Pablo joined Almirall in 2019 as Commercial ALMIRALL AND WUXI BIOLOGICS SIGN STRATEGIC COLLABORATION Barcelona, Spain January 9 th, 2020. Almirall, S.A. (ALM), and WuXi Biologics ("WuXi Bio") (2269.HK) have today announced the signing of an agreement. Through this collaboration Almirall embarks on its strategy to develop highly innovative biologic products for dermatology diseases including atopic dermatitis. IDENTITY MANAGER DASHBOARD Almirall Identity Access Copyright © 2021 Micro Focus. All rightsreserved.
ALMIRALL EXERCISES ITS OPTION WITH DERMIRA TO LICENSE BARCELONA, Spain and MENLO PARK, Calif. June, 25th 2019 . Almirall, S.A. (ALM) and Dermira, Inc. (NASDAQ: DERM) announced today that Almirall has exercised its option to license rights to develop and commercialize lebrikizumab for the treatment of atopic dermatitis and certain other indications in Europe. Almirall and Dermira previously entered into an option and license agreement in NEWS ROOM | ALMIRALL Almirall delivers on latest 2020 guidance and sets growth targets for 2021. The company delivered on its latest guidance despite a challenging year impacted by COVID-19 and the genericization of Aczone®: Net Sales €807.4 MM (-5.4%, flat excluding the Aczone® generic impact), Total Revenues €814.5 MM (-10.3%), EBITDA€238.3MM (-21.7%
ANNUAL ACCOUNTS AND FINANCIAL RESULTS 24/02/2020. FY 2019 Financial Results (audio) MP3. 24/02/2020. FY 2019 Financial Results presentation. PDF. 21/02/2020. Almirall at 38th JP Morgan Global Healthcare Conference, San Francisco. PDF. ALMIRALL’S 2020 FULL-YEAR RESULTS Almirall, S.A. (ALM) the global biopharmaceutical company based in Barcelona, has announced its full-year 2020 financial results today. Summary results. Net Sales of €807.4 MM represents a decline of 5.4% year-on-year, impacted both by COVID-19 and the generic competition to Aczone®. Net sales excluding the impact of the Aczone® generic CONTACT US | ALMIRALL Contact Us. Media For media enquiries please click on the link below. Media. You can request further information about Almirall by completing the form. All fields are compulsory, except those marked optional. Your name *. Your surnames *. Email *. Phone.ISSUES OF SHARES
Terms and Conditions of the Bonds PDF (601KB) Report regarding the bases and conversion terms of the Convertible Bonds (Spanish only) PDF (258KB) Independent Expert Report on the issue of Senior Convertible Bonds (Spanish only) PDF (1.6MB) Almirall announces the ALMIRALL AND WUXI BIOLOGICS SIGN STRATEGIC COLLABORATION Barcelona, Spain January 9 th, 2020. Almirall, S.A. (ALM), and WuXi Biologics ("WuXi Bio") (2269.HK) have today announced the signing of an agreement. Through this collaboration Almirall embarks on its strategy to develop highly innovative biologic products for dermatology diseases including atopic dermatitis. DIVIDENDS | ALMIRALL PDF. 08/05/2019. Scrip dividend calendar (only in Spanish) PDF. 11/06/2018. Information regarding the dividend payment (only in Spanish) PDF. 11/06/2018. Agreements taken in 2018 AGM (only inSpanish)
BOARD OF DIRECTORS
Joan Figueras Carreras. Vice Secretary (non-member) Mr. Figueras holds a Bachelor’s Degree in Laws from the Universitat de Barcelona and joined Almirall in 1993 as Senior Director of Legal Department, working in that position until 2013. Since then he is General Counsel of the company and Vice-Secretary of the Board of Directors. ALMIRALL AND TYRIS THERAPEUTICS ENTER INTO STRATEGIC Almirall, S.A. (BME:ALM), a global biopharmaceutical company based in Barcelona, and Tyris Therapeutics, a next generation gene therapy company founded by Columbus Venture Partners, have announced a strategic partnership today to tackle orphan dermatological conditions using non-viral gene therapies.By combining Tyris’s innovative non-viral based gene therapy technology and Almirall’s ALMIRALL EXERCISES ITS OPTION WITH DERMIRA TO LICENSE BARCELONA, Spain and MENLO PARK, Calif. June, 25th 2019 . Almirall, S.A. (ALM) and Dermira, Inc. (NASDAQ: DERM) announced today that Almirall has exercised its option to license rights to develop and commercialize lebrikizumab for the treatment of atopic dermatitis and certain other indications in Europe. Almirall and Dermira previously entered into an option and license agreement inFEEL THE SCIENCE
Almirall in Numbers. Our devotion to science and people can be measured. +100. Countries where we help patients. +1,780. Employees (53% women) 13. Countries Present within Europe and US. €78,9 M.OUR PRODUCTS
Vitamin B2. Vitamin B6. Vitamin C. Vitamin E. Xanthinol furosemide. Therapeutic Area Alimentary tract and metabolism Antiinfectives for systemic use Cardiovascular system Dermatologicals Genito urinary system and sex hormones Immunostimulants Metabolism Musculo-skeletal system Nervous system Respiratory system Systemic hormonalpreparations.
ANNUAL REPORTS
Annual Report. Our yearly figures. Discover how we have performed in 2020 and where we are heading in 2021. Information issued by the company to the National Stock Exchange Commission (CNMV). Annual Report 2020 PDF (7MB) Annual Report 2019 PDF (6.7MB) Annual Report2018 PDF (2.5MB)
INVESTOR RELATIONS
Almirall’s Leadership and Governance. As a publicly listed company and for the benefit of both the financial markets and the general public, Almirall pursues an open and active information policy. Learn more about our Corporate Governance.OUR NOBLE PURPOSE
Our noble purpose. Transform the patients' world by helping them realize their hopes and dreams for a healthy life. We are a leading skin health-focused biopharmaceutical company that partners with healthcare professionals to apply science to overcome patients’needs
PIPELINE - EXPERIENCE Almirall's pipeline reflects our commitment to the development of new medicines that help treat diseases in the future. Find out here! ALMIRALL AND MC2 THERAPEUTICS ENTER A LICENSE BARCELONA, Spain and COPENHAGEN, Denmark. February 17th, 2021 – Almirall S.A. (BME: ALM), a global biopharmaceutical company and MC2 Therapeutics, a commercial stage pharmaceutical company developing a new standard within topical therapies for autoimmune and chronic inflammatory conditions, announced today an agreement under which MC2 Therapeutics has granted AlmirallMANAGEMENT BOARD
Mr. Pablo Álvarez has a PhD in Pharmacy, with a focus on Microbiology from the Complutense University of Madrid (Spain). He carried out a postdoctoral research at MIT (Massachusetts, United States) and he has also studied business and management at IESE Business School in Barcelona (Spain). Pablo joined Almirall in 2019 as Commercial IDENTITY MANAGER DASHBOARD Almirall Identity Access Copyright © 2021 Micro Focus. All rightsreserved.
ALMIRALLSHARE, ALMIRALL OPEN INNOVATION PLATFORM Maximising the value of your preclinical assets to find a breakthrough therapy for patients. For scientists at Universities, Research institutions, biotechs, start-ups and pharmaceutical companies. Submit your proposal at any time. Pharmacological profile of your asset &FEEL THE SCIENCE
Almirall in Numbers. Our devotion to science and people can be measured. +100. Countries where we help patients. +1,780. Employees (53% women) 13. Countries Present within Europe and US. €78,9 M.OUR PRODUCTS
Vitamin B2. Vitamin B6. Vitamin C. Vitamin E. Xanthinol furosemide. Therapeutic Area Alimentary tract and metabolism Antiinfectives for systemic use Cardiovascular system Dermatologicals Genito urinary system and sex hormones Immunostimulants Metabolism Musculo-skeletal system Nervous system Respiratory system Systemic hormonalpreparations.
ANNUAL REPORTS
Annual Report. Our yearly figures. Discover how we have performed in 2020 and where we are heading in 2021. Information issued by the company to the National Stock Exchange Commission (CNMV). Annual Report 2020 PDF (7MB) Annual Report 2019 PDF (6.7MB) Annual Report2018 PDF (2.5MB)
INVESTOR RELATIONS
Almirall’s Leadership and Governance. As a publicly listed company and for the benefit of both the financial markets and the general public, Almirall pursues an open and active information policy. Learn more about our Corporate Governance.OUR NOBLE PURPOSE
Our noble purpose. Transform the patients' world by helping them realize their hopes and dreams for a healthy life. We are a leading skin health-focused biopharmaceutical company that partners with healthcare professionals to apply science to overcome patients’needs
PIPELINE - EXPERIENCE Almirall's pipeline reflects our commitment to the development of new medicines that help treat diseases in the future. Find out here! ALMIRALL AND MC2 THERAPEUTICS ENTER A LICENSE BARCELONA, Spain and COPENHAGEN, Denmark. February 17th, 2021 – Almirall S.A. (BME: ALM), a global biopharmaceutical company and MC2 Therapeutics, a commercial stage pharmaceutical company developing a new standard within topical therapies for autoimmune and chronic inflammatory conditions, announced today an agreement under which MC2 Therapeutics has granted AlmirallMANAGEMENT BOARD
Mr. Pablo Álvarez has a PhD in Pharmacy, with a focus on Microbiology from the Complutense University of Madrid (Spain). He carried out a postdoctoral research at MIT (Massachusetts, United States) and he has also studied business and management at IESE Business School in Barcelona (Spain). Pablo joined Almirall in 2019 as Commercial IDENTITY MANAGER DASHBOARD Almirall Identity Access Copyright © 2021 Micro Focus. All rightsreserved.
ALMIRALLSHARE, ALMIRALL OPEN INNOVATION PLATFORM Maximising the value of your preclinical assets to find a breakthrough therapy for patients. For scientists at Universities, Research institutions, biotechs, start-ups and pharmaceutical companies. Submit your proposal at any time. Pharmacological profile of your asset & NEWS ROOM | ALMIRALL Almirall delivers on latest 2020 guidance and sets growth targets for 2021. The company delivered on its latest guidance despite a challenging year impacted by COVID-19 and the genericization of Aczone®: Net Sales €807.4 MM (-5.4%, flat excluding the Aczone® generic impact), Total Revenues €814.5 MM (-10.3%), EBITDA€238.3MM (-21.7%
ALMIRALL’S 2020 FULL-YEAR RESULTS Almirall, S.A. (ALM) the global biopharmaceutical company based in Barcelona, has announced its full-year 2020 financial results today. Summary results. Net Sales of €807.4 MM represents a decline of 5.4% year-on-year, impacted both by COVID-19 and the generic competition to Aczone®. Net sales excluding the impact of the Aczone® genericCAREERS | ALMIRALL
Every medicine we develop, every product we market, every decision we make is focused on our Noble Purpose. Our purpose is our legacy for future generations and our contribution to society. So, no matter where in the company you will work, you can be sure that you will bemaking a
MANAGEMENT BOARD
Mr. Pablo Álvarez has a PhD in Pharmacy, with a focus on Microbiology from the Complutense University of Madrid (Spain). He carried out a postdoctoral research at MIT (Massachusetts, United States) and he has also studied business and management at IESE Business School in Barcelona (Spain). Pablo joined Almirall in 2019 as Commercial ALMIRALL ANNOUNCES FDA APPROVAL OF KLISYRI® (TIRBANIBULIN Barcelona (Spain), 15 December 2020. Almirall, S.A. (BME:ALM), a global biopharmaceutical company focused on skin health, announced today that Klisyri® (tirbanibulin) has been approved by the U.S. Food and Drug Administration (FDA) for the topical treatment of actinic keratosis (AK) of the face or scalp. Klisyri® (tirbanibulin) will be launched in the US during the first quarter of 2021. DISCOVER THE DIFFERENT SKIN TYPES Several criteria are used to classify the different types of skin.For example, Fitzpatrick's classification, first described in 1975, is based on skin color and its response to sun exposure. It is used to determine the proper type of sun protection factor or to predict the risk of skin cancer, among others.However, from a cosmetic point of view, skin is classified according to several factorsBOARD OF DIRECTORS
Joan Figueras Carreras. Vice Secretary (non-member) Mr. Figueras holds a Bachelor’s Degree in Laws from the Universitat de Barcelona and joined Almirall in 1993 as Senior Director of Legal Department, working in that position until 2013. Since then he is General Counsel of the company and Vice-Secretary of the Board of Directors. ALMIRALL AND TYRIS THERAPEUTICS ENTER INTO STRATEGIC Almirall, S.A. (BME:ALM), a global biopharmaceutical company based in Barcelona, and Tyris Therapeutics, a next generation gene therapy company founded by Columbus Venture Partners, have announced a strategic partnership today to tackle orphan dermatological conditions using non-viral gene therapies.By combining Tyris’s innovative non-viral based gene therapy technology and Almirall’s ALMIRALLSHARE, ALMIRALL OPEN INNOVATION PLATFORM Maximising the value of your preclinical assets to find a breakthrough therapy for patients. For scientists at Universities, Research institutions, biotechs, start-ups and pharmaceutical companies. Submit your proposal at any time. Pharmacological profile of your asset & OUR BEST PRESENT IS YOU Basic information regarding Data Protection Controller. Almirall S.A. Personal data processed. We process the personal data you provide us with during the registration process and also other personal information that we collect through the use of the platform, from a technical point of view and also through cookies.* Our Purpose
* go back Our Purpose Overview* Our Noble Purpose
* Your Health
* go back Your Health Overview* Your skin
* Your skin Your skin* Skin Conditions
* Skin Conditions Skin Conditions Overview* Psoriasis
* Actinic Keratosis
* Atopic Dermatitis
* Acne
* Onychomycosis
* Cutaneus T-Cell Lymphoma* Alopecia Areata
* Bullosa Epidermyosis* Skin Cancer
* Types of Skin
* About Skin
* More than skin
* Your skin More than skin Overview* Spasticity In MS
* Chronic Pain
* Commitment to patients * Report a side effect LIVING WITH PSORIASISYOU WORRY ABOUT…
* Psoriasis
* Actinic keratosis
* Atopic dermatitis
* Acne
View all skin conditions TAKE CARE OF YOUR SKIN* Types of skin
* About skin
MORE THAN SKIN…
* Spasticity in MS
* Chronic pain
* Our commitment to patient associations * Report a side effect* Our Expertise
* go back Our Expertise Overview * Research & Development * Research & Development Research & Development Overview* Pipeline
* Clinical Trials
* R&D Collaborations* Our disease focus
* Our Products
* Partnering
* HC Professional
* We care
* go back We care Overview * For the environment* For patients
* For employees
* For stakeholders
* For the environment For stakeholders Overview * Actions and initiatives by Almirall in response to the COVID-19crisis
* For transparency
* Media
* go back Media Overview* About Us
* Newsroom
* Media Resources
* Media Contact
* Investors
* go back Investors Overview* Share Information
* Share Information Share Information* Share Performance
* Share and capital structure* Shareholdings
* Takeover bids
* Dividends
* Share issues
* Analyst coverage
* Financial Data
* Share Information Financial Data * Financial results and accounts * Public Periodic Information* Factsheet
* Corporate presentations* Annual Report
* Significant Events* News
* Calendar
* Corporate Governance * Share Information Corporate Governance * Corporate governance presentation * Shareholders Annual General Meeting * Board of Directors* Board Commissions
* Management board
* Corporate governance annual reports * Agreements between significant shareholders * Average period of payments to suppliers* Careers
* go back Careers Overview* Life at Almirall
* Your Career
*
*
SELECT YOUR ALMIRALL* Germany
* Italy
* Netherlands
* Poland
* Spain
* Spain (Català)
* Austria
* Switzerland
* United Kingdom
* United States of AmericaView all results
* Highlights
* About People
* Choose Your Almirall * Almirall in numbers MEASURES TO MITIGATE the impact of COVID-19More
FEEL THE SCIENCE
Inspired to improve your lifeAbout us
DISCOVER MORE ABOUT
your skin, your health and how we can help youMore
WE STRIVE TO DEVELOP innovative and advanced solutions for youLearn more
CHECK OUR 2018 ANNUAL REPORTHere
WE CARE ABOUT TALENTLearn more
CREATING STRONG
relationships with healthcare professionals through knowledgeMore
MEASURES TO MITIGATE the impact of COVID-19More
FEEL THE SCIENCE
Inspired to improve your lifeAbout us
DISCOVER MORE ABOUT
your skin, your health and how we can help youMore
WE STRIVE TO DEVELOP innovative and advanced solutions for youLearn more
CHECK OUR 2018 ANNUAL REPORTHere
WE CARE ABOUT TALENTLearn more
CREATING STRONG
relationships with healthcare professionals through knowledgeMore
MEASURES TO MITIGATE the impact of COVID-19More
FEEL THE SCIENCE
Inspired to improve your lifeAbout us
DISCOVER MORE ABOUT
your skin, your health and how we can help youMore
WE STRIVE TO DEVELOP innovative and advanced solutions for youLearn more
CHECK OUR 2018 ANNUAL REPORTHere
WE CARE ABOUT TALENTLearn more
CREATING STRONG
relationships with healthcare professionals through knowledgeMore
IT'S ALL ABOUT PEOPLE Know the stories behind Almirall.Meet them all
Nerea talks about her experience with psoriasis.Discover More
Ignasi speaks about his daily life with psoriasis.Discover More
Guillaume talks about what it’s like to work at Almirall.View Story
CHOOSE YOUR ALMIRALL Find relevant content specifically selected for you.*
Patient
*
Investors
*
HC Professionals
*
Careers
OUR COMMITMENT STRENGTHENS OUR PURPOSE Get comprehensive details on our financial results, share performance, dividends and other financial matters, at a glance. CORPORATE GOVERNANCE View Almirall's Leadership and Governance.LIFE AT ALMIRALL
Find out what it is like to be part of Almirall. JOIN OUR TALENT COMMUNITY Explore a new career opportunity with us IMPROVING PATIENTS' HEALTH ACROSS THE WORLD THROUGH SCIENTIFICINNOVATION
Check Almirall's solutions portfolio. SHARING INNOVATION & MEDICAL RESOURCES Our science and experience at the service of your education. WHAT IS THE MAIN CAUSE OF PSORIASIS? Read more about the main causes of psoriasis, its symptoms and risk factors for this condition.WE CARE ABOUT YOU
We research and develop new products and solutions for you and futuregenerations
ALMIRALL IN NUMBERS
Our devotion to science and people can be measured+100
Countries where we help patients+1,750
Employees (53.5% women)13
Countries Present within Europe and US196.2 MM
Organic R&D and in-licensing payments€853.1
Million Company sales OUR SUPPLIERS, KEY TO DEPLOY OUR NOBLE PURPOSE Finding the right partners, aligned with our values and commitments with the health community, contributes to the success of our business.Go to Suppliers
QUICK LINKS
* Our purpose
* Your health
* Our expertise
* We care
* Stories
* Corporate GovernanceFIND YOUR ALMIRALL
* Media
* Investors
* Careers
* Partnering
* Suppliers
* HC Professionals
KEEP IN TOUCH
* Contact us
* Report a side effect * Subscribe to updateFOLLOW US
Find out the latest about Almirall at our social networks * 59CD2BBB-3B40-4519-9BFA-34066ED9DC2D Created with sketchtool. * B65C6E50-1BD0-4CD4-B046-33EE4DBB16BD Created with sketchtool. Copyright 2020 © Almirall, S.A All rights reserved* Privacy Policy
* Terms of Service
* Cookies
* Site map
We use our own and third-party cookies for statistical purposes. You can set your preferences (including rejection) or accept them all. If you need to learn more, please read our Cookie policyAccept All
Cookies Preference Center We use our own and third-party cookies for statistical purposes. You can set your preferences (including rejection) or accept them all. If you need to learn more, please read our Cookie policyTechnical Cookies
The use of technical cookies is necessary for this web page to function correctly. Without them, you may experience problems viewingthe page correctly.
Analysis Cookies
We use analysis cookies in order to obtain information on the performance of our web page. They allow us to detect areas in which we can improve your experience according to your use of the page.Save settings
Accept All
We are going to take you to a different platform This platform is safe as takes part of Almirall ecosystemCancel
Accept
You are about to leave WWW.ALMIRALL.COM Specific policies may apply to the site you are visiting; all interaction with that site is at your own risk.Cancel
Accept
The content you are about to see is restricted to media professionaluse
Please let us know if you are a professional to continue.Cancel
I'm a media professional The content you are about to see is restricted to HC Professional useonly
Please let us know if you are a HC Professional to continue.Cancel
I'm a HC ProfessionalDetails
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0